Metabolic & Cardiometabolic
ezetimibe does not increase diabetes risk
Part of: 💊 ezetimibe
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Human trials (RCT / n-of-1)
How the studies fall
What the evidence shows
Unlike high-intensity statins (which modestly raise new-onset diabetes risk), ezetimibe is glucose-NEUTRAL - no diabetogenic signal in IMPROVE-IT/RACING. Swapping some statin dose for ezetimibe may slightly reduce the regimen's glycemic burden. (Claim framed as 'does not increase diabetes risk'.)
The evidence (4)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM, IMPROVE-IT Investigators 2015 · N Engl J Med | RCT | supports | moderate | No increased incident diabetes with ezetimibe (vs statins' modest diabetogenic signal) — BUT glucose-neutrality was an unstated secondary outcome, inferred rather than a pre-specified endpoint. Quality downgraded from high on that basis. (Merged 2026-07-21 from two conflicting appraisals of the same source.) |
| Su PH, Tsai DH, Hsieh MH, Vairaperumal T, Lai EC, Liu PY 2026 · Communications medicine | observational | tested-null | low | Retrospective cohort (propensity-matched, n=7676 per arm) comparing bempedoic acid vs ezetimibe initiators for hyperuricemia; longitudinal glycemic measures were 'generally similar between groups' over 12 months. |
| Barkas F, Elisaf M, Liberopoulos E, Klouras E, Liamis G, Rizos EC 2016 · J Clin Lipidol | observational | supports | low | Retrospective Greek lipid-clinic cohort, 877 non-diabetic adults on dyslipidaemia treatment, median 7-y follow-up. In the PREDIABETIC subgroup (fasting glucose 100-125 mg/dL; subgroup n not given in abstract), statin + ezetimibe vs statin alone: incident diabetes adjusted OR 0.89 (95% CI 0.36-2.22, P>.05) - no increase and no demonstrated decrease; authors call ezetimibe 'neutral'. High-intensity statin vs moderate: OR 2.12 (1.06-4.24). Null vs the SPO 'ezetimibe decreases diabetes risk'. Abstract-only. |
| Perego C, Da Dalt L, Pirillo A, Galli A, Catapano AL, Norata GD 2019 · BBA Mol Basis Dis | mechanism | supports | low | Perego 2019 narrative review (Catapano/Norata, Milan) on cholesterol, beta-cell function and diabetes: 'clinical trials with lipid-lowering drugs other than statins, namely ezetimibe or monoclonal antibodies against PCSK9, did not observe an increase of developing diabetes.' Supports the negated claim in direction; a review restating trials, so zero weight (evidence_role: review). |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.